Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years
June 12 2019 - 01:00AM
Business Wire
Debiopharm and Ipsen extend and strengthen
their ongoing collaboration to ensure patient access to
Decapeptyl® for the treatment of certain urological,
gynecological and pediatric conditions
Regulatory News:
Debiopharm (Debiopharm – www.debiopharm.com) and Ipsen
(www.ipsen.com) today announced renewal of their Decapeptyl®
agreement, which extends and strengthens their strategic
partnership through 2034 for the development, manufacturing and
distribution of Decapeptyl® across Europe and certain Asian
and African markets. Having established their collaboration in the
1980s, this extension represents a long-term commitment to
patients, offering the benefits of Decapeptyl® in the treatment of
metastatic and non-metastatic patients with locally advanced
prostate cancer, endometriosis, uterine fibroids, central
precocious puberty and endocrine-responsive early-stage breast
cancer.
Under the renewed agreement, both parties will co-develop novel
formulations and explore additional indications for other patient
populations with high unmet needs.
“Our continued partnership remains critical to ensure that
patients maintain access to Decapeptyl® therapy for their various
conditions. Furthermore, this renewed agreement represents an
opportunity to refine and refocus our collaboration by further
exploring our co-development capacity to potentially identify how
Decapeptyl® can respond to more unmet patient needs.”Thierry
Mauvernay, President & Delegate of the Board Group,
Debiopharm
“We are delighted to renew and extend this partnership with
Debiopharm. This collaboration has been - and continues to be - a
testament to our commitment to patients and our shared passion with
strategic partners.”Ivana Magovčević-Liebisch, Executive
Vice-President, Chief Business Officer
About Decapeptyl®
Decapeptyl® (triptorelin pamoate) is an agonist analogue
of the natural gonadotropin-releasing hormone (GnRH), currently
available in three sustained-release formulations (1, 3 and 6
months). First registered in France in 1986, triptorelin is
currently marketed in more than 80 countries, being the market
leader in many territories worldwide. The alliance between
Debiopharm and Ipsen for Decapeptyl® has successfully delivered
sustained market growth with €372.6 million total sales in 2018,
representing 8.1% annual growth.
About Debiopharm
Debiopharm aims to develop innovative therapies that target high
unmet medical needs in oncology and bacterial infections. Bridging
the gap between disruptive discovery products and real-world
patient reach, the company identifies high-potential compounds for
in-licensing, clinically demonstrate their safety and efficacy and
then select large pharmaceutical commercialization partners to
maximize patient access globally. For more information on
Debiopharm, visit www.debiopharm.com and follow @DebiopharmNews at
http://twitter.com/DebiopharmNews.
About Ipsen
Ipsen is a global specialty-driven biopharmaceutical group
focused on innovation and Specialty Care. The group develops and
commercializes innovative medicines in three key therapeutic areas
- Oncology, Neuroscience and Rare Diseases. Its commitment to
Oncology is exemplified through its growing portfolio of key
therapies for prostate cancer, neuroendocrine tumors, renal cell
carcinoma and pancreatic cancer. Ipsen also has a well-established
Consumer Healthcare business. With total sales over €2.2 billion in
2018, Ipsen sells more than 20 drugs in over 115 countries, with a
direct commercial presence in more than 30 countries. Ipsen's
R&D is focused on its innovative and differentiated
technological platforms located in the heart of the leading
biotechnological and life sciences hubs (Paris-Saclay, France;
Oxford, UK; Cambridge, US). The Group has about 5,700 employees
worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the
United States through a Sponsored Level I American Depositary
Receipt program (ADR: IPSEY). For more information on Ipsen, visit
www.ipsen.com.
Forward Looking Statement
The forward-looking statements, objectives and targets contained
herein are based on the Group’s management strategy, current views
and assumptions. Such statements involve known and unknown risks
and uncertainties that may cause actual results, performance or
events to differ materially from those anticipated herein. All of
the above risks could affect the Group’s future ability to achieve
its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today.
Use of the words "believes", "anticipates" and "expects" and
similar expressions are intended to identify forward-looking
statements, including the Group’s expectations regarding future
events, including regulatory filings and determinations. Moreover,
the targets described in this document were prepared without taking
into account external growth assumptions and potential future
acquisitions, which may alter these parameters. These objectives
are based on data and assumptions regarded as reasonable by the
Group. These targets depend on conditions or facts likely to happen
in the future, and not exclusively on historical data. Actual
results may depart significantly from these targets given the
occurrence of certain risks and uncertainties, notably the fact
that a promising product in early development phase or clinical
trial may end up never being launched on the market or reaching its
commercial targets, notably for regulatory or competition reasons.
The Group must face or might face competition from generic products
that might translate into a loss of market share. Furthermore, the
Research and Development process involves several stages each of
which involves the substantial risk that the Group may fail to
achieve its objectives and be forced to abandon its efforts with
regards to a product in which it has invested significant sums.
Therefore, the Group cannot be certain that favorable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will
be sufficient to demonstrate the safe and effective nature of the
product concerned. There can be no guarantees a product will
receive the necessary regulatory approvals or that the product will
prove to be commercially successful. If underlying assumptions
prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the
forward-looking statements. Other risks and uncertainties include
but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of pharmaceutical
industry regulation and health care legislation; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the Group's ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the Group’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The Group also depends on third parties to develop and market some
of its products which could potentially generate substantial
royalties; these partners could behave in such ways which could
cause damage to the Group’s activities and financial results. The
Group cannot be certain that its partners will fulfil their
obligations. It might be unable to obtain any benefit from those
agreements. A default by any of the Group’s partners could generate
lower revenues than expected. Such situations could have a negative
impact on the Group’s business, financial position or performance.
The Group expressly disclaims any obligation or undertaking to
update or revise any forward-looking statements, targets or
estimates contained in this press release to reflect any change in
events, conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. The
Group’s business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des Marchés
Financiers. The risks and uncertainties set out are not exhaustive
and the reader is advised to refer to the Group’s 2018 Registration
Document available on its website (www.ipsen.com).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190611005884/en/
Debiopharm ContactDawn HaughtonCommunication
Managerdawn.haughton@debiopharm.comTel: +41 (0)21 321 01 11Ipsen
ContactChristian MarcouxSenior Vice President, Global
Communications RelationsChristian.marcoux@ipsen.comTel: +33 (0)1 58
33 67 94Ipsen - Financial CommunityEugenia LitzVice
President, InvestorEugenia.litz@ipsen.comTel: +44 (0) 1753
627721
Ipsen (EU:IPN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ipsen (EU:IPN)
Historical Stock Chart
From Mar 2023 to Mar 2024